QR Code

A forgotten option: megestrol acetate’s effectiveness and safety in HR+/HER2-negative metastatic breast cancer — insights from a contemporary patient cohort

BACKGROUND: The ABC 6/7 guidelines recommend megestrol acetate (MA) as a later-line hormonal option for HR+/HER2− metastatic breast cancer (MBC) when targeted therapies are unavailable, though current evidence on its efficacy and safety remains limited. MATERIALS AND METHODS: This retrospective stud...

Full description

Saved in:
Main Authors: Marek Ziobro, Renata Pacholczak-Madej, Aleksandra Grela-Wojewoda, Marcin Kubeczko, Miroslawa Puskulluoglu
Format: Artigo
Language:Inglês
Published: Via Medica 2026-05-01
Series:Reports of Practical Oncology and Radiotherapy
Subjects:
metastatic breast cancer
megestrol acetate
hormonal agents
efficacy
adverse events
Online Access:https://journals.viamedica.pl/rpor/article/view/110809
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items